Catalyst Pharmaceutical Inc. (CPRX)
Catalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. The company's flagship product is Firdapse, used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting nerve-muscle communication. Catalyst is dedicated to advancing treatments for patients with rare conditions through innovative research and development.
Company News
Catalyst Pharmaceuticals and SERB S.A. reached a settlement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE, allowing Lupin to market a generic version starting February 2035, with ongoing litigation against Hetero still pending.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat ...
These two healthcare stocks may be deeply undervalued.